Consultation

Best-Value Biological Medicine: Filgrastim

The HSE-Medicines Management Programme (MMP) is undertaking a formal consultation phase as part of the process for the identification of a best-value biological (BVB) medicine for filgrastim.

The MMP roadmap for the prescribing of best-value biological (BVB) medicines in the Irish healthcare setting outlines the criteria that may be considered by the MMP in identifying the BVB medicine for filgrastim.

Submissions are invited from all relevant stakeholders, and should be emailed to mmp@hse.ie by 5pm on Wednesday 21st September 2022.

Best-Value Biological Medicine: Long-acting Granulocyte-Colony Stimulating Factors

The HSE-Medicines Management Programme (MMP) is undertaking a formal consultation phase as part of the process for the identification of a best-value biological (BVB) medicine for long-acting granulocyte-colony stimulating factor (i.e. lipegfilgrastim/pegfilgrastim).

The MMP roadmap for the prescribing of best-value biological (BVB) medicines in the Irish healthcare setting outlines the criteria that may be considered by the MMP in identifying the BVB medicine for long-acting granulocyte-colony stimulating factor (i.e. lipegfilgrastim/pegfilgrastim).

Submissions are invited from all relevant stakeholders, and should be emailed to mmp@hse.ie by 5pm on Thursday 22nd September 2022.